Variability in COVID-19 Vaccine Response Among People With Cancer

Abstract

high-quality care. How can we do better if we do not require reporting race and ethnicity in phase 3 clinical trials for prostate cancer that ultimately define our standard of care? Deliberate efforts in reporting the diversity of participants in clinical trials are needed if we are ever to eliminate the persistent health disparities in prostate cancer mortality or scientific advances will continue to not reach historically marginalized and excluded populations.

Topics & Concepts